ERJ staff report (TP)
Essen, Germany – Evonik Industries and the University of Tokyo plan to work together closely in selected fields in the future and have sealed a strategic partnership for this purpose.
Representatives signed a contract at the launch of the scientific forum, Evonik Meets Science, in Tokyo. "We are very interested in sharing knowledge and our research results with society. Collaborations with industry are a great way to accomplish this," said Prof. Dr. Shigeo Kagami, General Manager of the Office of Innovation and Entrepreneurship, Division of University Corporate Relations. "We therefore welcome the partnership with Evonik as a leading specialty chemicals company."
The university, which employs 1,267 full professors, 901 associate professors and boasts 27,998 students (14,120 undergraduates and 13,878 graduates), has produced numerous prime ministers and Nobel Prize winners.
This is now Evonik’s fourth strategic university partner. Such partnerships already exist with the University of Minnesota in the US, the Shanghai Jiao Tong University (SJTU) in China, and with King Abdullah University of Science and Technology (KAUST) in Saudi Arabia.
Additionally, in autumn 2013, Evonik signed a memorandum of understanding regarding a strategic partnership with the Agency for Science, Technology, and Research (A*STAR), the leading major national research institution in Singapore.
Strategic partnerships with universities in all important regions of the world create a framework for Evonik for joint research projects and a regular sharing of research trends in science and industry.
The expansion of innovation activities in economically attractive regions supports Evonik’s growth strategy. The goal is to strengthen local customer competitiveness with technological services as well as research and application techniques that fit local needs.
An example in Asia is the R&D centre in Shanghai which was expanded in 2013 for the third time. In total, Evonik invested €23m in the 14,000-square-metre building with 50 laboratories.
Evonik said it has raised R&D expenditure by an average of 9 percent a year since 2009. Expenditure amounted to €394m in 2013, compared to €382m in 2012. The R&D quota was 3.1 percent. Expenditure on R&D is also expected to remain at a high level in the future.
This is an external link and should open in a new window. If the window does not appear, please check your pop-up blocking software. ERJ is not responsible for the content of external sites.
Press release from Evonik